Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum

Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023...

Related Keywords

Puerto Rico ,Bangladesh ,China ,Indiana ,United States ,Taiwan ,Japan ,Saudi Arabia ,Jordan ,Davida Ricks ,Cheplapharm Arzneimittel Gmb ,Eli Lilly ,Joe Fletcher ,Prnewswire Eli Lilly ,International Agencies Ltd ,Securities Exchange ,Drug Administration ,Exchange Commission ,Insulin Value Program ,Research Development ,Boehringer Ingelheim ,Amphastar Pharmaceuticals Inc ,New Products ,Growth Products ,New Drug Application ,Cheplapharm Arzneimittel Gmbh ,Amphastar Pharmaceuticals ,International Agencies ,Priority Review ,Emergency Use ,Securities Act ,Securities Exchange Act ,Financial Accounting Standards Board ,Months Ended March ,Eli Lilly And Company ,